Skip to main content
Fig. 4 | Allergy, Asthma & Clinical Immunology

Fig. 4

From: Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis

Fig. 4

Time to achieve a 50% and 75% reduction in T4NSS or T5SS after treatment with rupatadine 10 mg or 20 mg, or placebo. a Proportion of responders over time for the 50% response in T4NSS. b Time (days) to achieve a 50% proportion of responders for the T4NSS or T5SS (50% response). c Proportion of responders over time for the 75% response in T4NSS. d Time (days) to achieve a 25% proportion of responders for the T4NSS or T5SS (75% response). T4NSS Total 4 Nasal Symptom Score, T5SS Total 5 Symptom Score

Back to article page